MCID: HYD002
MIFTS: 60

Hydronephrosis

Categories: Nephrological diseases

Aliases & Classifications for Hydronephrosis

Summaries for Hydronephrosis

MalaCards based summary : Hydronephrosis is related to vesicoureteral reflux 1 and ureteral obstruction. An important gene associated with Hydronephrosis is WFS1 (Wolframin ER Transmembrane Glycoprotein), and among its related pathways/superpathways are Colorectal Cancer Metastasis and Interleukin-4 and 13 signaling. The drugs Midazolam and Propofol have been mentioned in the context of this disorder. Affiliated tissues include kidney, prostate and spinal cord, and related phenotypes are homeostasis/metabolism and behavior/neurological

Wikipedia : 74 Hydronephrosis describes dilation of the renal pelvis and calyces as a result of obstruction to urine... more...

Related Diseases for Hydronephrosis

Diseases related to Hydronephrosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 650)
# Related Disease Score Top Affiliating Genes
1 vesicoureteral reflux 1 32.1 TGFB1 C12orf57 B2M ALB
2 ureteral obstruction 32.0 TGFB1 SLC12A1 AQP2
3 acute cystitis 31.9 IL6 CCL2 ALB
4 urinary tract obstruction 31.8 TGFB1 EGF CCL2 B2M AQP2 ALB
5 pyelonephritis 31.7 TGFB1 IL6 CCL2 AQP2 ALB
6 diabetes insipidus 31.5 WFS1 SLC12A1 AQP2
7 obstructive nephropathy 31.5 TGFB1 EGF CCL2 ALB
8 cystitis 31.5 VEGFA IL6 EGF CCL2
9 acute kidney failure 31.4 EGF B2M ALB
10 appendicitis 31.3 IL6 CCL2 ALB
11 cystic kidney disease 31.2 EGF B2M AQP2 ALB
12 kidney disease 31.1 TGFB1 SLC12A1 IL6 CCL2 B2M AQP2
13 pyelitis 31.1 IL6 B2M ALB
14 bacteriuria 31.1 IL6 CCL2 ALB
15 peritonitis 31.1 IL6 CCL2 B2M ALB
16 posterior urethral valves 31.0 TGFB1 IL6
17 pyuria 31.0 IL6 B2M ALB
18 glomerulonephritis 30.9 TGFB1 CCL2 B2M ALB
19 xanthogranulomatous pyelonephritis 30.9 EGF CCL2
20 obstructive jaundice 30.8 TGFB1 IL6 CCL2 ALB
21 intussusception 30.8 VEGFA IL6 ALB
22 chronic kidney disease 30.8 VEGFA TGFB1 IL6 CCL2 B2M AQP2
23 intestinal obstruction 30.8 VEGFA IL6 GATA4 FLNA ALB
24 nephrosclerosis 30.8 VEGFA TGFB1 CCL2
25 diabetes mellitus 30.8 WFS1 VEGFA TGFB1 IL6 CCL2 B2M
26 diarrhea 30.7 TGFB1 MME IL6 FLNA ALB
27 syphilis 30.7 IL6 B2M ALB
28 interstitial cystitis 30.7 VEGFA IL6 EGF
29 ureteral disease 30.7 TGFB1 IL6 CCL2 AQP2 ALB
30 uremia 30.5 IL6 B2M ALB
31 varicose veins 30.5 VEGFA IL6 CCL2
32 polycystic kidney disease 30.5 VEGFA EGF AQP2 ALB
33 gastric ulcer 30.5 VEGFA IL6 EGF
34 congestive heart failure 30.4 VEGFA MME IL6 GATA4 AQP2 ALB
35 exanthem 30.4 VEGFA IL6 ALB
36 neurofibromatosis, type ii 30.4 VEGFA IL6 EGF ALB
37 patent ductus arteriosus 1 30.4 ZIC3 VEGFA GATA4 FLNA ALB
38 membranous nephropathy 30.4 MME B2M ALB
39 suppression of tumorigenicity 12 30.4 VEGFA IL6 EGF ALB
40 chorioamnionitis 30.4 VEGFA IL6 CCL2
41 bone inflammation disease 30.4 VEGFA IL6 CCL2 ALB
42 peripheral artery disease 30.4 VEGFA IL6 CCL2
43 mucositis 30.3 VEGFA TGFB1 EGF
44 eclampsia 30.3 VEGFA IL6 ALB
45 diffuse large b-cell lymphoma 30.3 VEGFA MME IL6 B2M
46 vascular disease 30.3 VEGFA TGFB1 IL6 CCL2 ALB
47 autosomal dominant polycystic kidney disease 30.2 VEGFA TGFB1 EGF CCL2 AQP2 ALB
48 schistosomiasis 30.2 VEGFA CCL2 ALB
49 plasmacytoma 30.2 VEGFA IL6 B2M
50 osteoporosis 30.1 VEGFA TGFB1 IL6 EGF CCL2 B2M

Comorbidity relations with Hydronephrosis via Phenotypic Disease Network (PDN): (show all 36)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Bladder Cancer
Bladder Neck Obstruction Candidiasis
Cervical Cancer Colorectal Cancer
Cystitis Cystitis Cystica
Decubitus Ulcer Deficiency Anemia
Intestinal Obstruction Iron Deficiency Anemia
Kidney Disease Nephrolithiasis, Uric Acid
Nephrolithiasis, X-Linked Recessive, with Renal Failure Nephrosclerosis
Neurogenic Bladder Neutropenia
Ovarian Cancer Paralytic Ileus
Prostate Cancer Prostatic Hypertrophy
Protein-Energy Malnutrition Pyelonephritis
Radiation Cystitis Rectosigmoid Junction Neoplasm
Renal Pelvis Carcinoma Ureter, Cancer of
Ureterolithiasis Urethral Benign Neoplasm
Urethral Calculus Urethral Stricture
Urinary Tract Obstruction Vesicoureteral Reflux 1

Graphical network of the top 20 diseases related to Hydronephrosis:



Diseases related to Hydronephrosis

Symptoms & Phenotypes for Hydronephrosis

MGI Mouse Phenotypes related to Hydronephrosis:

45 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.35 ALB AQP2 B2M C12orf57 FLNA GATA4
2 behavior/neurological MP:0005386 10.34 AQP2 FLNA ID2 IL6 MME SETBP1
3 cellular MP:0005384 10.31 ALB B2M FLNA GATA4 ID2 IL6
4 growth/size/body region MP:0005378 10.31 AQP2 B2M EGF FLNA GATA4 ID2
5 mortality/aging MP:0010768 10.3 ALB AQP2 B2M C12orf57 FLNA GATA4
6 cardiovascular system MP:0005385 10.29 ALB B2M FLNA GATA4 IL6 OSR1
7 digestive/alimentary MP:0005381 10.26 ALB B2M EGF FLNA GATA4 ID2
8 immune system MP:0005387 10.23 ALB B2M CCL2 EGF FLNA ID2
9 endocrine/exocrine gland MP:0005379 10.21 ALB B2M EGF GATA4 ID2 IL6
10 integument MP:0010771 10.21 AQP2 B2M EGF GATA4 ID2 IL6
11 liver/biliary system MP:0005370 10.06 ALB B2M FLNA GATA4 IL6 MME
12 nervous system MP:0003631 10.06 B2M FLNA GATA4 ID2 IL6 MME
13 normal MP:0002873 9.91 ALB EGF FLNA GATA4 ID2 OSR1
14 renal/urinary system MP:0005367 9.81 ALB AQP2 ID2 IL6 OSR1 SLC12A1
15 reproductive system MP:0005389 9.73 AQP2 B2M EGF FLNA GATA4 ID2
16 respiratory system MP:0005388 9.23 FLNA GATA4 IL6 OSR1 TGFB1 TSHZ3

Drugs & Therapeutics for Hydronephrosis

Drugs for Hydronephrosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 109)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
2
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
3
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
4
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
5
Etomidate Approved Phase 4 33125-97-2 36339 667484
6
Silodosin Approved Phase 4 160970-54-7
7
Sodium citrate Approved, Investigational Phase 4 68-04-2
8
tannic acid Approved Phase 4 1401-55-4
9
Allopurinol Approved Phase 4 315-30-0 2094
10
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
11
Potassium citrate Approved, Investigational, Vet_approved Phase 4 866-84-2
12
Ceftriaxone Approved Phase 4 73384-59-5 5361919 5479530
13
Vancomycin Approved Phase 4 1404-90-6 14969 441141
14
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
15
Uric acid Investigational Phase 4 69-93-2 1175
16 Hypnotics and Sedatives Phase 4
17 Anti-Anxiety Agents Phase 4
18 Hydrocortisone 17-butyrate 21-propionate Phase 4
19 Anesthetics, General Phase 4
20 Psychotropic Drugs Phase 4
21 GABA Modulators Phase 4
22 Hydrocortisone hemisuccinate Phase 4
23 Anesthetics, Intravenous Phase 4
24 Adrenergic alpha-Antagonists Phase 4
25 Adrenergic Antagonists Phase 4
26 Adrenergic Agents Phase 4
27 Adrenergic alpha-1 Receptor Antagonists Phase 4
28 diuretics Phase 4
29 Antirheumatic Agents Phase 4
30 Respiratory System Agents Phase 4
31 Citrate Phase 4
32 Antioxidants Phase 4
33 Expectorants Phase 4
34 Protective Agents Phase 4
35 penicillins Phase 4
36
Alfuzosin Approved, Investigational Phase 3 81403-80-7 2092
37
Fluorouracil Approved Phase 3 51-21-8 3385
38 Pharmaceutical Solutions Phase 3
39
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 2 437-38-7 3345
40
Gemcitabine Approved Phase 2 95058-81-4 60750
41
Acetylcholine Approved, Investigational Phase 2 51-84-3 187
42 Anti-Infective Agents Phase 2
43 Immunologic Factors Phase 2
44 Immunosuppressive Agents Phase 2
45 Antimetabolites Phase 2
46 Antiviral Agents Phase 2
47 Neurotransmitter Agents Phase 2
48 abobotulinumtoxinA Phase 2
49 Botulinum Toxins, Type A Phase 2
50 Cholinergic Agents Phase 2

Interventional clinical trials:

(show top 50) (show all 103)
# Name Status NCT ID Phase Drugs
1 Phase 1 Study of Circadian Rhythm of Salivary Cortisol in Health Children ;Phase 2 Study of Circadian Rhythm of Salivary Cortisol of Children Undergoing Surgery Using Etomidate or Not Using Etomidate. Unknown status NCT02013986 Phase 4 etomidate;midazolam;propofol
2 A 4-week, Double-blind, Randomized, Comparative and Multi-center Clinical Trial to Evaluate the Efficacy and Safety of Silodosin in the Treatment of Natural Expulsion in Patients With Ureteral Stones. Completed NCT01533389 Phase 4 Silodosin;Placebo
3 The Predictors of Successful Oral Dissolution Therapy in Radiolucent Renal Stones; A Prospective Evaluation Completed NCT02373384 Phase 4 Oral alkalinization (Potassium citrate, Allopurinol)
4 The EDGE Consortium: A Randomized Trial of Preoperative Prophylactic Antibiotics Prior to Percutaneous Nephrolithotomy: Part 1 Completed NCT02384200 Phase 4 nitrofurantoin monohydrate/macrocrystalline capsules;ampicillin;gentamicin;vancomycin;ceftriaxone
5 Does An Abnormal PFA 100 Predict Bleeding After Renal Biopsy? Terminated NCT00334204 Phase 4
6 12-week, Multicenter, Open-label, Non-comparative Study to Investigate Pharmacodynamic and Safety of Alfuzosin 0.2 mg/kg/Day in the Treatment of Children and Adolescents 2 - 16 Years of Age With Hydronephrosis Associated With Elevated Detrusor Leak Point Pressure of Neuropathic Etiology Followed by a 40-week Open-label Extension Completed NCT00576823 Phase 3 Alfuzosin
7 Randomized Phase III Study of 5-FU Continuous Infusion (5FUci) Versus MTX+5-FU Sequential Therapy (MF) in Gastric Cancer With Peritoneal Metastasis (JCOG0106-MF, MF/5FU) Completed NCT00149201 Phase 3 5-FU continuous infusion;MTX + 5-FU sequential therapy
8 Randomized Controlled Trial of Fetal Cystoscopy Versus Vesico-amniotic Shunting in Severe Lower Urinary Tract Obstructions Unknown status NCT01552824 Phase 2
9 A Phase II Clinical Trial to Evaluate the Potential of Concomitant Chemoradiotherapy With Gemcitabine in Patients With Locally Advanced Carcinoma of Cervix and Renal Disease Recruiting NCT03101995 Phase 2 Gemcitabine
10 Botulinum Toxin A Treatment of Detrusor External Sphincter Dyssynergia During Early Spinal Cord Injury (Protocol #H-20344) Terminated NCT00711087 Phase 2 BOTOX-A
11 The Correlation Between Renal Injury and Biomarkers in Pediatric Ureteropelvic Junction Obstruction Patients Unknown status NCT01711996
12 Ureteropelvic Junction Obstruction in Early Childhood: Comparison of Surgical Therapy and Surveillance in Children With Scintigraphically Prooved Obstruction. A Prospective, Randomized, Controlled Multi-Center Study Unknown status NCT00444431
13 Bladder Function Following Temporary Unilateral Cutaneous Ureterostomy - Long Term Follow up Unknown status NCT00546208
14 Sonographic Follow up in Newborns Diagnosed With Prenatal Hydronephrosis Unknown status NCT01780103
15 Cortical Transit Time on Diuretic Renogram as an Early Marker of Significant Obstruction in Antenatally Detected Uretero-pelvic Junction Syndrome Unknown status NCT02812212
16 Part 1 The Outcome of Children With Melamine-Related-Calculus Unknown status NCT00895765
17 Ureteral Reimplantation for the Treatment of Extrinsic Malignant Ureteral Obstruction Unknown status NCT02160652
18 Conventional Antibiotic Prophylaxis Versus Add-On 5 Days Levofloxacin Before Percutaneous Nephrolithotomy (PCNL) Unknown status NCT03178292 Levofloxacin;Placebo
19 The Use of Tamsulosin in Treatment of (10-15 mm) Lower Ureteric Stones in Adults With Non-emergent Symptoms: A Prospective Randomized Study Unknown status NCT03274700 Early Phase 1 Tamsulosin.;Placebo.
20 Incidence of Post Cystography Urinary Tract Infections in the Pediatric Population Unknown status NCT03399682
21 Evaluation of Two Different Treatments for Lower Pore Renal Stone: Microperc Vs FURS Unknown status NCT03307096
22 Assessment of Flexible Ureteroscopy Residual Fragments Unknown status NCT02434068
23 Keller Fire Rescue Study of Prehospital Ultrasound Use Unknown status NCT01074112
24 Ciprofloxacin Prophylaxis in Retrograde Intrarenal Surgery: a Prospective Randomized Trail in Comparison of Multiple-, Single- and Zero-dose. Unknown status NCT02304822 Multiple-dose of Ciprofloxacin prophylaxis;Single-dose of Ciprofloxacin prophylaxis;Zero-dose of Ciprofloxacin prophylaxis
25 Prevalence of Pediatric Urolithiasis in Kashgar Area of Xinjiang in China: a Population and Ultrasonography Based Cross-sectional Study Unknown status NCT03003312
26 Correlation of Hydronephrosis on Point of Care Ultrasound With CT Finding in Patients With Expected Renal Colic Completed NCT01349244
27 Urinary Biomarkers as Predictors on Renal Function in Congenital Hydronephrosis Completed NCT00568724
28 Hydronephrosis After Anterior Lumbar Interbody Fusion (ALIF) Completed NCT02976870
29 Simplified Diagnostic Algorithm for Evaluation of Neonates With Prenatally Detected Hydronephrosis Completed NCT01330511
30 Emergency Department Targeted Ultrasound for the Detection of Hydronephrosis Completed NCT00555308
31 Hydro II: Emergency Department Ultrasound in Renal Colic Completed NCT01323842
32 Evaluation of Ultrasound Acoustic Radiation Force Impulse (ARFI)Shear Wave Velocity Imaging (SVI)in the Characterization of Pediatric Hydronephrosis Completed NCT01781845
33 Clinical Significance of Supranormal Differential Renal Function in the Recovery of Unilateral Hydronephrosis After Surgery: Long-term Results Completed NCT01839006
34 Sensitivity and Specificity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in an Emergency Room Population Completed NCT00786708
35 Bedside Ultrasonography in Acute Patients With Suspected Kidney Involvement Completed NCT03873701
36 Dismembered Pyeloplasty With and Without After Coming Stent in Neonatal Ureteropelvic Junction Obstruction Completed NCT02138877
37 Evaluation of Ureteral Length Measurement by Computed Tomography (CT) to Actual Ureteral Length Measured by Ureteral Catheterization Completed NCT01542593
38 Incidence of and Risk Factors for Perioperative Infection Among Patients Undergoing Radical Cystectomy Completed NCT03290742
39 Use of the PercSys MicroStent Device to Alleviate Ureteral Stone Symptoms and Hydronephrosis Completed NCT01637519
40 Role of Clinical and Urodynamic Risk Factors for Recurrent Urinary Tract Infection in 5-18 Years Old Children Completed NCT00528476
41 The Effects of Water Versus Saline on Absorption Rates and Visualization During Ureteroscopy Completed NCT03794102
42 Efficacy Of Pulsed Electromagnetic Field Therapy On Neurogenic Bladder in Children With Myelomeningocele Completed NCT04187027
43 Acute Kidney Injury in Premature Infants Completed NCT00573079
44 Prospective Pediatric Pyeloplasty Robotic Surgical Database Completed NCT00882544
45 Post Approval Study: MR Guided Focused Ultrasound Surgery in the Treatment of Uterine Fibroids Completed NCT00166270
46 Comparative Study of Extracorporeal Shock Wave Lithotripsy and Ureteroscopy in Management of Upper Third Ureteral Calculi Completed NCT03559738
47 The Influence of Transmission Season on Outcome of Schistosoma Haematobium Infection Treatment Among School Children in Urban and Peri-Urban Areas of Maputo and Matola, Mozambique Completed NCT00231322 praziquantel
48 Effect of Double J Stent on Outcomes of Extracorporeal Shock Wave Lithotripsy Treatment of Moderate Sized Renal Pelvic Stones: A Randomized Prospective Study Completed NCT03636516
49 Accuracy of Surgeon-performed Ultrasound in Detecting Gallstones - a Validation Study Completed NCT02469935
50 Feasibility and Impact of a Decision Rule for Imaging of Emergency Department Patients With Suspected Kidney Stone Completed NCT01869647

Search NIH Clinical Center for Hydronephrosis

Cochrane evidence based reviews: hydronephrosis

Genetic Tests for Hydronephrosis

Genetic tests related to Hydronephrosis:

# Genetic test Affiliating Genes
1 Hydronephrosis 29

Anatomical Context for Hydronephrosis

MalaCards organs/tissues related to Hydronephrosis:

40
Kidney, Prostate, Spinal Cord, Colon, Cervix, Testes, Bone

Publications for Hydronephrosis

Articles related to Hydronephrosis:

(show top 50) (show all 11042)
# Title Authors PMID Year
1
Role of the angiotensin receptor in the development of the mammalian kidney and urinary tract. 54 61
11137441 2001
2
In fetuses with isolated hydronephrosis, urinary beta 2-microglobulin and N-acetyl-beta-D-glucosaminidase (NAG) have a limited role in the prediction of postnatal renal function. 54 61
8994243 1996
3
Developmental expression of two members of a new class of transcription factors: I. Expression of aryl hydrocarbon receptor in the C57BL/6N mouse embryo. 61 54
8589437 1995
4
[Evaluation of renal function and prediction of renal functional recovery in children with unilateral hydronephrosis using renal pelvic urine]. 54 61
1282579 1992
5
Multi-route antifungal administration in the management of urinary Candida glabrata bezoar. 61
32489899 2020
6
Retrocaval ureter with ureteral calculus: Case report. 61
32518758 2020
7
An 82-year-old female with chest pain radiating to the back and flank. 61
32420036 2020
8
Severe ureteropelvic junction obstruction with massive hydronephrosis causing compression of the inferior vena cava. 61
32477882 2020
9
Neglected double J stent for 8 Years with giant bladder calculi formation: A case report. 61
32322528 2020
10
Pelvic hemangiopericytoma: A case report and review of the literature. 61
32435596 2020
11
Surgical outcomes of segmental ureteral resection with ureteroneocystostomy after major gynecologic surgery. 61
32278519 2020
12
Prenatal diagnosis of renal duplication by magnetic resonance imaging. 61
30572758 2020
13
The significance of preoperative estimated glomerular filtration rate on survival outcomes in patients who underwent radical cystectomy and non-continent urinary diversion. 61
32213208 2020
14
Bulk motion-compensated DCE-MRI for functional imaging of kidneys in newborns. 61
31837071 2020
15
Bacterial spectrum and antibiotic resistance of urinary tract infections in patients treated for upper urinary tract calculi: a multicenter analysis. 61
32557326 2020
16
Pediatric bladder augmentation - Panacea or Pandora's box? 61
31977304 2020
17
Delayed Decompression of Obstructing Stones with Urinary Tract Infection is Associated with Increased Odds of Death. 61
32501124 2020
18
Development and external validation of a preoperative nomogram for predicting pathological locally advanced disease of clinically localized upper urinary tract carcinoma. 61
32253820 2020
19
Cine magnetic resonance urography for postoperative evaluation of reconstructive urinary tract after ileal ureter substitution: initial experience. 61
32106934 2020
20
Validation of the effectiveness of a modified Studer orthotopic neobladder in a single center after 3 years of its application. 61
32567527 2020
21
Urinary kidney injury molecule-1: a novel biomarker to monitor renal function in patients with unilateral ureteral obstruction. 61
32507943 2020
22
Ultrasound findings in urogenital schistosomiasis: a pictorial essay. 61
31494862 2020
23
URINARY TRACT ANOMALIES IN PATIENTS WITH ANORECTAL MALFORMATIONS: THE ROLE OF SCREENING AND CLINICAL FOLLOW-UP. 61
32525076 2020
24
Ultrasound Markers in Fetal Hydronephrosis to Predict Postnatal Surgery. 61
29975970 2020
25
Laparoscopic laterally extended endopelvic resection procedure for gynecological malignancies. 61
32332122 2020
26
Temporal Trends and Practice Patterns for Inpatient Management of Malignant Extrinsic Ureteral Obstruction in the United States. 61
32340482 2020
27
Comparison of routine pelvic US and MR imaging in patients with pathologically confirmed endometriosis. 61
31300849 2020
28
Tract dilation monitored by ultrasound in percutaneous nephrolithotomy: feasible and safe. 61
31312892 2020
29
Pediatric bilateral ureteral stone successfully removed using single-use flexible ureteroscopy with a holmium: YAG laser. 61
32577268 2020
30
Baseline renal function and renal ultrasound findings in patients with obstetric fistulas (RENFRU): a prospective cohort study. 61
31961472 2020
31
[The 478 th case: multiple myalgia with intramuscular nodules]. 61
32486593 2020
32
Managing children with hydronephrosis: common pitfall during ultrasound follow-up to remember. 61
31300410 2020
33
Correlation of Antenatal Ultrasound Parameters with the Postnatal Outcome of Bilateral Fetal Hydronephrosis. 61
32476766 2020
34
Point-of-care ultrasound for the detection of hydronephrosis in emergency department patients with suspected renal colic. 61
32507905 2020
35
Robot-assisted Pyeloureterostomy in the Treatment of the Lower Pole Ureteropelvic Junction Obstruction in an Incomplete Duplicated System. 61
32561363 2020
36
Changes in differential renal function after pyeloplasty in infants and children. 61
32146062 2020
37
Laparoscopic nephron-sparing surgery for a tumor near the isthmus of a horseshoe kidney with a complicated blood supply. 61
32489122 2020
38
Relevance of concurrent hypercalcemia in ureteric sarcoidosis complicated with bladder urothelial carcinoma: a case report. 61
32571234 2020
39
Vesicocutaneous fistula: continent vesicostomy, an easier route for comfortable clean intermittent catheterization. 61
32171665 2020
40
PCNL in COPD patient in the sit position under local infiltration anesthesia case report. 61
32552883 2020
41
Guidelines for the medical management of pediatric vesicoureteral reflux. 61
32239562 2020
42
Resolution of Hydronephrosis in Children with Dysfunctional Voiding After Biofeedback Therapy: A Randomized Clinical Trial. 61
32556710 2020
43
Fetal lower urinary tract obstruction: What should we tell the prospective parents? 61
32065667 2020
44
Paternal mosaicism for a novel PBX1 mutation associated with recurrent perinatal death: Phenotypic expansion of the PBX1-related syndrome. 61
32141698 2020
45
IgG4-related aortitis/periaortitis and periarteritis: a distinct spectrum of IgG4-related disease. 61
32366271 2020
46
CT Findings of Upper Urinary Tract Lesions in IgG4-Related Disease: Comparison With Urothelial Carcinoma. 61
32374662 2020
47
Comparative Study of Retroperitoneal Laparoscopic Versus Open Ipsilateral Nephrectomy After Percutaneous Nephrostomy: A Multicenter Analysis. 61
32027216 2020
48
Ureteral Reimplantation via Robotic Nontransecting Side-to-Side Anastomosis for Distal Ureteral Stricture. 61
32233674 2020
49
Feline abdominal ultrasonography: what's normal? what's abnormal? The kidneys and perinephric space. 61
32326858 2020
50
The Feasibility, Safety, and Efficacy of the Preemptive Indwelling of Double-J Stents in Percutaneous Nephrolithotomy Surgery: A Randomized Controlled Trial. 61
32309876 2020

Variations for Hydronephrosis

ClinVar genetic disease variations for Hydronephrosis:

6 (show all 13) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 WFS1 NM_006005.3(WFS1):c.1999C>T (p.Gln667Ter)SNV Pathogenic 598973 rs771409809 4:6303521-6303521 4:6301794-6301794
2 TBX4 NM_001321120.2(TBX4):c.402G>A (p.Trp134Ter)SNV Pathogenic 638159 17:59544871-59544871 17:61467510-61467510
3 C12orf57 NM_138425.4(C12orf57):c.53-2A>GSNV Pathogenic 242885 rs1114167293 12:7053637-7053637 12:6944474-6944474
4 46;XY;inv(6)(p22q13)dninversion Pathogenic 267941
5 PGM1 NM_002633.3(PGM1):c.804T>A (p.Tyr268Ter)SNV Likely pathogenic 694645 1:64100621-64100621 1:63634950-63634950
6 SETBP1 NM_015559.3(SETBP1):c.2614G>A (p.Gly872Arg)SNV Likely pathogenic 523513 rs1555706928 18:42531919-42531919 18:44951954-44951954
7 CHN1 NM_001822.7(CHN1):c.667G>A (p.Ala223Thr)SNV Likely pathogenic 598971 rs1558939623 2:175689207-175689207 2:174824479-174824479
8 KIF1A NM_001244008.1(KIF1A):c.3052C>T (p.His1018Tyr)SNV Uncertain significance 598972 rs1356639316 2:241686664-241686664 2:240747247-240747247
9 XDH NM_000379.4(XDH):c.1172C>T (p.Pro391Leu)SNV Uncertain significance 598996 rs1558697792 2:31602803-31602803 2:31379937-31379937
10 GATA4 NM_002052.5(GATA4):c.94G>C (p.Ala32Pro)SNV Uncertain significance 599008 rs773545065 8:11565915-11565915 8:11708406-11708406
11 ERF NM_006494.4(ERF):c.1636C>T (p.Arg546Ter)SNV Uncertain significance 599007 rs764412749 19:42752628-42752628 19:42248476-42248476
12 FLNA NM_001110556.2(FLNA):c.3934C>T (p.Arg1312Cys)SNV Uncertain significance 617640 rs781928289 X:153588145-153588145 X:154359777-154359777
13 XDH NM_000379.4(XDH):c.3647C>A (p.Pro1216His)SNV Uncertain significance 335760 rs143981573 2:31562482-31562482 2:31339616-31339616

Expression for Hydronephrosis

Search GEO for disease gene expression data for Hydronephrosis.

Pathways for Hydronephrosis

GO Terms for Hydronephrosis

Cellular components related to Hydronephrosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 platelet alpha granule lumen GO:0031093 8.92 VEGFA TGFB1 EGF ALB

Biological processes related to Hydronephrosis according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.02 ZIC3 VEGFA TGFB1 TBX4 OSR1 IL6
2 negative regulation of transcription by RNA polymerase II GO:0000122 9.99 WFS1 VEGFA TGFB1 TBX4 OSR1 ID2
3 negative regulation of apoptotic process GO:0043066 9.97 VEGFA OSR1 IL6 FLNA ALB
4 positive regulation of transcription, DNA-templated GO:0045893 9.88 ZIC3 TGFB1 IL6 ID2 GATA4 EGF
5 angiogenesis GO:0001525 9.86 VEGFA TBX4 EGF CCL2
6 cellular protein metabolic process GO:0044267 9.8 WFS1 IL6 B2M ALB
7 positive regulation of gene expression GO:0010628 9.8 VEGFA TGFB1 OSR1 IL6 ID2 EGF
8 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.74 VEGFA TGFB1 IL6
9 negative regulation of DNA-binding transcription factor activity GO:0043433 9.71 WFS1 ID2 FLNA
10 positive regulation of epithelial cell proliferation GO:0050679 9.63 VEGFA TGFB1 OSR1
11 positive regulation of MAP kinase activity GO:0043406 9.61 VEGFA TGFB1 EGF
12 lung development GO:0030324 9.56 ZIC3 VEGFA TBX4 MME
13 positive regulation of vascular permeability GO:0043117 9.55 VEGFA TGFB1
14 positive regulation of vascular endothelial growth factor production GO:0010575 9.54 TGFB1 IL6 GATA4
15 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.52 TGFB1 IL6
16 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.46 VEGFA TGFB1 IL6 EGF
17 mammary gland alveolus development GO:0060749 9.13 VEGFA ID2 EGF
18 platelet degranulation GO:0002576 9.02 VEGFA TGFB1 FLNA EGF ALB

Molecular functions related to Hydronephrosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA-binding transcription factor activity, RNA polymerase II-specific GO:0000981 9.63 ZIC3 TSHZ3 TBX4 OSR1 ID2 GATA4
2 cytokine activity GO:0005125 9.26 VEGFA TGFB1 IL6 CCL2
3 growth factor activity GO:0008083 8.92 VEGFA TGFB1 IL6 EGF

Sources for Hydronephrosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....